Valneva’s chikungunya vaccine Ixchiq has been greenlit by the UK’s MHRA, allowing the single-dose vaccine to be made ...

Valneva has announced positive outcomes from its Phase III VLA1553-321 trial of the single-shot IXCHIQ chikungunya virus ... potentially leading to label extension in Europe, Canada, and the ...

Those findings have supported the submission of label extension applications for Ixchiq in the U.S., Europe, and Canada, targeting the vaccine’s use in adolescents.

The company said the updated results from the phase 3 VLA1553-321 trial “strengthen” the pivotal data previously reported for Ixchiq in adolescents, which supported label extension applications for ...

The Business Research Company's Ixchiq Global Market Report 2025 – Market Size, Trends, And Forecast 2025-2034 Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase ...

(RTTNews) - Valneva SE (VALN) a specialty vaccine company, on Wednesday announced that it is advancing to a Phase 3 trial for IXCHIQ, its single-dose chikungunya vaccine, in children aged 1 to 11 ...

Valneva submitted label extension applications to the U.S. Food and Drug Administration (FDA) 5, the European Medicines Agency (EMA) and Health Canada 6 to potentially extend the use of IXCHIQ ...

Valneva submitted label extension applications to the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) and Health Canada to potentially extend the use of Ixchiq to ...